A Study of a Novel Precision Medicine Approach for Obesity
Phase 4
135
about 3.8 years
18–65
2 sites in FL, MN
About this study
Researchers are testing whether a saliva biomarker can predict how well semaglutide works to treat obesity. The trial will last 1378 days and involve approximately 135 participants. Participants will be assigned to receive either a placebo or semaglutide.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Semaglutide
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
semaglutide (GLP-1 agonist; stimulates insulin release)
oral (Oral Tablet)
Primary: Change in Total Body Weight at 24 weeks
Secondary: Change in Total Body Weight at 3 months, Change in Total Body Weight at 6 months, Change in Waist Circumference
Endocrinology